



CERTIFICATE OF MAILING  
UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313 on

21 March 2005

HUESCHEN AND SAGE

Michelle M. Cus  
Dated: 21 March 2005

SERVIER 403 DIV

\*\*\*\*\*

Applicant : Gilbert LAVIELLE, Olivier MULLER, Mark MILLAN, and  
Alain GOBERT  
Serial No. : 10/813,347  
Filed : March 30, 2004  
Title : Indoline Compounds  
Art Unit : 1625  
Examiner : Evelyn M. HUANG, Esq.

\*\*\*\*\*

Honorable Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313

SUPPLEMENTAL RESPONSE UNDER 37 CFR § 1.111

Sir:

Responsive to the Office action, dated October 15, 2004, **and to supplement the Response and Amendment of March 14, 2005**, please find enclosed herewith a copy of Form PTO-1449 (which was submitted with the previous Response) and the remaining references which accompany this form.


\*\*\*\*\*

It should be apparent that the undersigned attorney has made an earnest effort to place this application into condition for immediate allowance. If he can be of assistance to the Examiner in the elimination of any possibly-outstanding insignificant impediment to an immediate allowance, the Examiner is respectfully invited to call him at his below-listed number for such purpose.

Allowance is solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

By: 

G. PATRICK SAGE

Dated: March 21, 2005  
Customer No.: 25,666  
500 Columbia Plaza  
350 East Michigan Ave.  
Kalamazoo, MI 49007-3856  
(269) 382-0030

Enclosure: Copy of PTO-Form 1449 and Accompanying References (references 8, 21, and 22) and Postal Card Receipt

\*\*\*\*\*

**THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.**

PTO-1449	ATTY. DOCKET NO. SERVIER 403 DIV	SERIAL NO. 10/813,347
LIST OF PRIOR ART CITED BY APPLICANT	APPLICANT G. LAVIELLE, O. MULLER, M. MILLAN, and A. GOBERT	
SHEET 1 OF 3	FILING DATE March 30, 2004	GROUP 1625



#### U.S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE


#### FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
					YES	NO

#### OTHER PRIOR ART


	BERENDSEN, et al., <i>Psychopharmacology</i> , <b>1990</b> , 101, 57-61.
	MILLAN, et al., <i>European Journal of Pharmacology</i> , <b>1997</b> , 325, 9-12.
	O'NEILL, et al., <i>Pharmacology, Biochemistry, and Behavior</i> , <b>1999</b> , 63, 237-243.
	REAVILL, et al., <i>British Journal of Psychopharmacology</i> , <b>1999</b> , 126, 572-574.
	HERRICK-DAVIS, et al., <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2000</b> , 295, 226-232.
	WOOD, et al., <i>Drug Development Research</i> , <b>2001</b> , 54, 88-94.
	PAIVA, et al., <i>Psychopharmacology</i> , <b>1988</b> , 96, 395-399.
	DUGOVIC, <i>Journal Sleep Research</i> , <b>1992</b> , 1, 1163-1168.
	LANDOLT, et al., <i>Neuropsychopharmacology</i> , <b>1999</b> , 21, 455-466.
	SHARPLEY, et al., <i>Biological Psychiatry</i> , <b>2000</b> , 47, 468-470.
	WATSON, et al., <i>Pharmacology, Biochemistry, and Behavior</i> , <b>1991</b> , 39, 605-612.

EXAMINER	DATE CONSIDERED
<p><b>*EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

PTO-1449	ATTY. DOCKET NO. SERVIER 403 DIV	SERIAL NO. 10/813,347
LIST OF PRIOR ART CITED BY APPLICANT		
SHEET 2 OF 3		
	APPLICANT G. LAVIELLE, O. MULLER, M. MILLAN, and A. GOBERT	
	FILING DATE March 30, 2004	GROUP 1625

**OTHER PRIOR ART**

	FOREMAN, et al., <i>Life Sciences</i> , <b>1989</b> , 45, 1263-1270.
	KLINT, et al., <i>Psychopharmacology</i> , <b>1995</b> , 119, 291-294.
	HIRSCHFELD, <i>Journal of Clinical Psychiatry</i> , 60 Suppl. 17:32-35, <b>1999</b> .
	POPOVA, et al., <i>Neuroendocrinology</i> , <b>2002</b> , 76, 28-34.
	Amesergide, LY-237733; <i>Pharmaproject</i> , Phase II Clinical Trial, <b>2005</b>
	KOSKINEN, et al., <i>Pharmacology, Biochemistry and Behavior</i> , <b>2000</b> , 66, 729-738.
	WHITE, et al., <i>Pharmacology, Biochemistry and Behaviour</i> , <b>1991</b> , 39, 729-736.
	MILLAN, et al., <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2001</b> , 298, 581-591.
	MUNDO, et al., <i>International Clinical Psychopharmacology</i> , <b>2000</b> , 15, 69-76.
	MILLAN, et al., <i>Prog. Neurobiol.</i> , <b>1999</b> , 57, 1-164.
	MILLAN, et al., <i>Prog. Neurobiol.</i> , <b>2002</b> , 66, 355-474.
	KALKMAN, et al., <i>Int. J. Clin. Pharmacol. Res.</i> , <b>1997</b> , 17, 75-77.
	KALKMAN, et al., <i>Naunyn Schmiedebergs. Arch. Pharmacol.</i> , <b>1994</b> , 350, 225-229.
	KALKMAN, et al., <i>Life Sci.</i> , <b>1994</b> , 54, 641-644.
	Ro-60-0759, <i>Pharmaproject</i> , Preclinical Trial, <b>2005</b>
	SB-243213, <i>Pharmaproject</i> , Phase I Clinical Trial, <b>2005</b>
EXAMINER	DATE CONSIDERED
<p><b>*EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

PTO-1449	ATTY. DOCKET NO. SERVIER 403 DIV	SERIAL NO. 10/813,347
LIST OF PRIOR ART CITED BY APPLICANT		
SHEET 3 OF 3		
	APPLICANT G. LAVIELLE, O. MULLER, M. MILLAN, and A. GOBERT	
	FILING DATE March 30, 2004	GROUP 1625

#### OTHER PRIOR ART

	LY-053857, <i>Pharmaproject</i> , Phase II Clinical Trial (2005).
	KANT, <i>Pharmacol. Biochem. Behav.</i> , 1998, 59, 729-735.
	MENESES, et al., <i>Behav. Brain Res.</i> , 1997, 87, 105-110.
	KANT, <i>Pharmacol. Biochem. Behav.</i> , 1996, 53, 385-390.
	DI GIOVANNI, et al., <i>Indian J. Exp. Biol.</i> , 2002, 40, 1344-1352.
	DE DEURWAERDERE, et al., <i>Trends Pharmacol. Sci.</i> , 2001, 22, 502-504.
	MILLAN, et al., <i>Neuropharmacology</i> , 1998, 37, 953-955.
	FOX, et al., <i>Drug News and Perspectives</i> , 1999, 12:477-483.
	FOX, et al., <i>Movement Disorders</i> , 2000, 15:1064-1069.
	SM-3163, <i>Pharmaproject</i> , Phase II Clinical Trial (2005).
EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	